

Iowa Medicaid Drug Utilization Review (DUR) Commission

May 1, 2024

Location‡: Virtual Only

Time: 9:30 a.m. – 1:30 p.m. CT

Meeting Link: https://teams.microsoft.com/join/19%3ameeting_YzEzY2Y4ZmYtNmE1ZS00MjZjLWFmNDQtMzdiODIyMTAzNmJm%40thread.v2/0?context=%7b%22Tid%22%3a%228d2c7b4d-085a-4617-8536-38a76d19b0da%22%2c%22Oid%22%3a%22982a0572-2333-4ea7-b2e0-b02af2367c61%22%7d

Dial In: 1-469-998-6046

Meeting ID: 224 374 463 892

Meeting Password: 6Wd3B4

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
2. Commission Business
 - a) Approval of the February 7, 2024 Meeting Minutes
 - b) February 2024 DUR Recommendation Letter to DHHS
 - c) Follow-Up from Previous Meeting(s)
3. Iowa Medicaid Pharmacy Update
4. Prevalence Report Summaries
 - a) Molina Healthcare of Iowa
 - b) Iowa Total Care
 - c) Wellpoint Iowa
 - d) Comparative Summary
5. Public Comment* (**See attached Conflict of Interest Disclosure**)
 - Verbal - Must pre-register to provide verbal public comment and submit a completed conflict of interest disclosure. Five (5) minute maximum limit.
 - Written – Must submit written comments and a completed conflict of interest disclosure.
 - **All submissions must be received no later than 4:30 p.m. CT April 24, 2024.**
 - Send to info@iadur.org
6. Retrospective DUR
 - a) Data Presentation(s)
 - i. Antianxiety/Sedatives in Children
 - ii. Mood Stabilizers in Children – Updated
 - iii. Low Dose Quetiapine in Children – Updated
 - iv. Concurrent use of Levetiracetam and Clobazam
 - b) Proposal(s)
 - i. Stimulant Medication Utilization without Supporting Diagnosis
 - ii. Non-Selective Beta-Blockers in Asthma

- c) Commission Recommendations for Retrospective DUR Agenda Topics
- 7. Break (10 minutes)
- 8. Prior Authorization
 - a) Antidiabetic Non-Insulin Agents – Initial review
 - b) Biologicals for Axial Spondyloarthritis – Initial Review
 - c) Biologicals for Inflammatory Bowel Disease – Initial Review
 - d) Biologicals for Plaque Psoriasis – Initial Review
 - e) Janus Kinase Inhibitors – Initial Review
 - f) Omalizumab (Xolair) – Initial Review
 - g) Biologicals for Arthritis – Second Review
 - h) Biologicals for Hidradenitis Suppurativa – Second Review
 - i) Dupilumab (Dupixent) – Second Review
 - j) Febuxostat (Uloric) – Removal of Criteria – Second Review
 - k) Select Preventative Migraine Treatments – Second Review
 - l) Hepatitis C Treatment, Direct Acting Antivirals – Second Review

9. Miscellaneous

- a) DUR Digest Vol. 36, No. 2 – Initial Review

10. MedWatch

[FDA revises letter of authorization for the emergency use authorization for Paxlovid](#)

[FDA Approves First Medication to Help Reduce Allergic Reactions to Multiple Foods After Accidental Exposure](#)

[FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight](#)

[FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease](#)

[FDA Approves Nonsteroidal Treatment for Duchenne Muscular Dystrophy](#)

11. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Any individual speaking, presenting, or providing written comment for virtual meetings must complete a conflict of interest disclosure. Completed forms must be provided to DUR staff at least one week prior to the scheduled meeting at info@iadur.org. Speakers who fail to submit or turn in their conflict-of-interest disclosure form late will have their request to speak denied or will not have their comments shared.

‡ Always check the DUR website for updates regarding meeting location, as this can change after the initial posting of the agenda.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515) 974-3131.

**Next Meeting
August 7, 2024
Location: TBD**